Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Public Health Professionals
- Remove People with Substance Use or Abuse Problems as Audience
- Remove Parents & Caregivers
- Remove Substance Abuse
- Remove Opioid Use Disorder
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Adolescents as Population Group
- Remove People with Mental Health Problems as Population Group
- Remove Opioids or Opiates
- Remove Buprenorphine
- Remove Medication-Assisted Treatment
- Remove Treatment
Main page content
Published: December 2021This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health
Published: September 2017This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.
Published: March 2011Esta hoja de hechos ofrece informacion a los pacientes sobre la buprenorfina y los tratamientos con ayuda de medicamentos para tratar el trastorno por uso de opioides, y tambien describe el mal uso y los sintomas del sindrome de abstinencia. Explica como funciona la buprenorfina, su uso apropiado, sus efectos secundarios y como se la utiliza en conjunto con al consejeria en el proceso de recuperacion.